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Background. There is a controversy within the medical community regarding the role of domperidone as a galactagogue and the
drug has been removed from the US market owing to safety concerns. Objective. To perform a systematic review and meta-analysis
of the available data assessing the eﬀect of domperidone on breast milk production in women experiencing insuﬃcient lactation.
Study Selection. Randomized controlled trials (RCTs) examining the eﬀect of domperidone on breast milk production of puerperal
w omenwer eeligibleforinclusion.DataAnalysis.Absoluteandrelativechangesfrombaselinewerecalculatedforindividualstudies
a n dp o o l e du s i n gar a n d o me ﬀects model. Results. Three RCTs including 78 participants met the inclusion criteria. All showed a
statistically signiﬁcant increase in breast milk production following treatment with domperidone. The analysis of pooled data
demonstrated a statistically signiﬁcant relative increase of 74.72% (95% CI = 54.57;94.86,P<0.00001) in daily milk production
with domperidone treatment compared to placebo. No maternal or neonatal adverse events were observed in any of the trials.
Conclusions. Evidence from a few small RCTs of moderate to high quality suggests that domperidone produces a greater increase
in breast milk supply than placebo.
1.Introduction
The beneﬁts of breastfeeding are well recognized for both the
mother and baby; thus, eﬀorts should be made to promote
initiation, duration, and exclusivity of breastfeeding [1]. The
recently published survey of Canadian women who gave
birth and were residing with their infants at the time of
the interview has found that breastfeeding intention and
initiating rates were fairly high, 90% and 90.3%, respectively,
among women of this representative sample [2]. However,
reportedexclusivebreastfeedingratesatthreeandsixmonths
fell substantially—51.7% and 14.4%. While factors that
aﬀect breastfeeding success are multiple and nonmodiﬁable
at times, the early recognition and timely management
of modiﬁable risk factors is warranted to improve lacta-
tion performance [3]. Various nonpharmacological inter-
ventions have been shown to be eﬀective and hence are
incorporated in the current clinical recommendations for
promoting breastfeeding [1]. Among them are individual
and group breastfeeding education provided by lactation
specialists, peer counseling, in-person, or telephone support.
Pharmacological interventions to improve lactation, mainly
dopamine antagonists, are usually recommended only after
nonpharmacological modalities have failed, and this is
largely due to scarcity of available evidence and potential
safety issues with pharmaceutical galactagogues [4, 5].
Domperidone, a peripheral dopamine receptor antag-
onist, is believed to enhance breast milk production
by increasing prolactin secretion [6–8]. It has a favor-
able safety proﬁle when compared to metoclopramide,
another dopamine receptor antagonist, with only rare extra-
pyramidal side eﬀects owing likely to poor blood-brain
barrier penetration of domperidone [9–11] .T h ed r u gi sw e l l
tolerated with relatively few side eﬀects reported including
headache,drymouth,andabdominalcramps[10,12].While
domperidoneisnotavailableforanyindicationintheUnited
States due to arrhythmia concerns, it is approved in Canada
and other countries as a prokinetic agent. Moreover, there is2 Obstetrics and Gynecology International
aworldwideexperiencewithdomperidoneintreatingnausea
and vomiting. The use of domperidone as a galactagogue,
hence, represents an “oﬀ-label” indication.
In2004,theUnitedStatesFoodandDrugAdministration
(FDA) issued an advisory against the use of domperidone
as a milk enhancer due to safety concerns [13]. There
have been a few reports of cardiac arrhythmia and sudden
death in cancer patients treated with intravenous domperi-
done which are often cited in the literature [14]. Rapid
intravenous administration or high doses of domperidone
as well as concurrent hypokalemia might be signiﬁcant
contributors to these adverse outcomes leading to discon-
tinuation of the intravenous route of administration. A
single case report of reversible QT prolongation associated
with oral domperidone administration has been published
[15]. In neonates, oral administration of domperidone
was associated with QT prolongation [16]. Whereas the
potential pro-arrhythmic eﬀect of domperidone should not
be ignored, the FDA concern over the use of domperidone
for promoting lactation has been regarded by lactation
experts as a gross overestimation. Available pharmacoki-
netic data, although limited, indicates minimal excretion
of domperidone into breast milk with extremely low (less
than 0.01% of the maternal weight-adjusted dose) infant
exposure via breast milk [6–8, 12]. No side eﬀects have been
reportedinexposedinfants.TheAmericanAcademyofPedi-
atrics lists domperidone as compatible with breastfeeding
[17].
Nevertheless, there is a controversy regarding the role of
domperidone as a galactagogue: some authors claim no or
little eﬀectiveness, largely due to limitations of available data
[18] while other researchers suggested that domperidone
is a galactagogue of choice based on evidence available
[4]. This situation might be a source of confusion in the
medicalcommunityand,therefore,maycompromiseclinical
management decisions.
The objective of our study was to perform a systematic
review and meta-analysis of the available data assessing the
eﬀect of domperidone on breast milk supply in women
experiencing insuﬃcient breast milk production.
2. Methods
2.1. Eligibility Criteria. Randomized controlled trials (RCTs)
examining the eﬀect of domperidone on breast milk pro-
duction were considered for inclusion. We utilized the
PICO format (population, intervention, comparison, and
outcome) to develop our clinical question, guide the lit-
erature search, and assess eligibility of potentially relevant
studies. The population of interest was puerperal women
who had experienced insuﬃcient lactation after delivery.
We accepted any deﬁnition of insuﬃcient lactation, with
the most common deﬁnition being milk supply below the
infant’s daily oral feeding requirements. The intervention
considered for this paper was domperidone treatment to
augment lactation; the comparator considered was placebo
or no treatment. The outcome of interest was percent change
in daily breast milk volume after domperidone treatment.
2.2. Search Strategy. The following electronic databases
were searched: Ovid MEDLINE(R) (1948 to May 2011),
EMBASE (1947 to May 2011), and Cochrane Library, with
no restrictions on language or year of publication. The last
searchwasrunonMay312011.Oursearchstrategyincluded
the following National Library of Medicine Medical Subject
Headings (MeSH) terms: “domperidone” combined with
“lactation” OR “milk production” OR “galactagogue” OR
“breastfeeding.” The search was limited further to human
data and clinical trials. Reference lists of relevant review
papers andall selectedarticles were handsearchedto identify
additional trials.
2.3.StudySelectionandQualityAssessment. Literaturesearch
and eligibility assessment was performed independently by
two reviewers. One reviewer extracted the data and per-
formed quality assessment of included trials. The second
reviewer checked the extracted data and quality assessment.
Disagreements in judgment between reviewers were resolved
by discussion. The following data was extracted: characteris-
tics of trial participants (number, inclusion criteria), type of
intervention (dose and duration of domperidone or placebo
treatment), outcome measure (type and assessment tool),
and maternal and neonatal adverse eﬀects reported.
Study quality was assessed using the GRADE (grading
of recommendations, assessment, development, and evalu-
ation) system [21]. The GRADE system was developed by
a widely representative group of scientists and adopted by
the Cochrane Collaboration to assess the quality of evidence
for outcomes reported in systematic reviews. Each individual
study was rated as that of high, moderate, low, or very
low quality. The Cochrane Collaboration’s tool has been
applied to assess risk of bias across studies. The following
domains were evaluated—sequence generation, blinding,
allocation concealment, incomplete outcome data, selective
outcome reporting, and other sources of bias. Randomized
controlled trials are generally rated as a high quality but
might be downgraded. Factors that may decrease the quality
ofevidenceincludeseriouslimitationsindesign,imprecision
of results, unexplained heterogeneity, and indirectness of
evidence and high probability of publication bias.
2.4. Statistical Analysis. The primary eﬀect measure for
this paper was the change in daily breast milk volume
from baseline to the end of the treatment presented as
am e a nd i ﬀerence and standard deviation. Absolute and
relative changes from baseline were recorded for individual
studies. Absolute mean diﬀerences in daily breast milk
volumes before and after treatment were extracted from
individual studies. Relative mean diﬀerences were calculated
as percentage change from baseline.
When the standard deviations of the absolute changes
from baseline were not available from individual studies,
we imputed them as described in detail in the Cochrane
Handbook [22–24]. In brief, we calculated correlation
coeﬃcients from one available study which reported the
means and standard deviations for change in breast milk
volume from baseline [8]. Using the imputed correlation
coeﬃcients values, we thereafter calculated a change fromObstetrics and Gynecology International 3
Total number of records identiﬁed: 24
Ovid MEDLINE (3)
EMBASE (11)
Cochrane Library (10)
Number of records after duplicates removed: 18
Number of records screened: 18
Number of articles assessed for eligibility as a full text: 12
Number of articles included
in review and meta-analysis: 3
Review paper (4)
Number of articles excluded: 9
No population of interest (1)
No outcome of interest (2)
No comparator of interest (1)
No full text available (1)
Number of records excluded: 6
Not relevant (5)
Case report (1)
Figure 1: Flow chart of selected studies.
baseline standard deviations for the other studies with
missing standard deviations [19, 20]. A sensitivity analysis
was performed utilizing the lowest and highest values of the
correlation coeﬃcient to determine the robustness of the
results.
The standard deviations of relative change (%) were
calculated as SDrelative change = SDabsolutechange/breast milk
volumebaseline. Pooled estimates of the weighted mean diﬀer-
ences and 95% CI were calculated using a random eﬀects
model. The I
2 statistic was used to assess the extent of
heterogeneity among studies. A priori subgroup analyses
were not planned. Due to insuﬃcient number of studies, a
formal assessment of reporting bias by visual inspection of a
funnel plot was not possible.
3. Results
3.1. Study Selection. T h el i t e r a t u r es e a r c hr e t r i e v e dat o t a l
of 24 citations (Figure 1). After duplicate publications were
eliminated, 18 remaining abstracts were screened for eligi-
bility. Of these, six were excluded (ﬁve were deemed not
relevant and one was a case report). The full text of the
remaining 12 citations was analyzed further in detail. Nine
papers were excluded due to various reasons. Three studies
mettheinclusioncriteriaandwereincludedinthesystematic
review and meta-analysis [8, 19, 20].
3.2. Study Characteristics. All three studies selected for this
review were randomized, placebo-controlled trials with a
total of 78 patients enrolled (37 in domperidone group
and 41 in placebo group) [8, 19, 20]. Table 1 summarizes
characteristics of included studies. All participants have
experienced inadequate breast milk production postpartum
and,therefore,wererandomizedtodomperidoneorplacebo.
Of note, all mothers were enrolled after a few weeks post-
partum allowing time to establish lactation and/or receive
appropriate lactation support. However, only one study
mentioned extensive lactation counseling prior to enrolment
[8].
The dose of domperidone used across the studies was
30mg/d (10mg orally 3 times daily). The length of the
treatment ranged from 7 to 14 days. All studies reported
the change in daily milk production from baseline to the
end of the treatment. In Petraglia et al. [19], the mothers
breastfed their full-term infants, and thus daily milk volumes
were assessed by weighing the babies before and after
breastfeeding. In two other studies [8, 20], the mothers
pumped breast milk to feed their preterm babies and the
amount of milk expressed was recorded.
3.3. Methodological Quality of Included Studies. Table 2 dis-
plays the summary of risk of bias for individual studies
included in the meta-analysis. Two of the studies, by Da
Silva et al. [8] and Campbell-Yeo et al. [20], were ranked as
having low risk of bias. The description of randomization,
allocation concealment, blinding, and reporting in these two
papers was judged as adequate. Da Silva et al. [8], however,
reported incomplete or nonreturned records for three out of
11 participants in the domperidone group which represents
missing data for >25% of participants. Overall, both studies4 Obstetrics and Gynecology International
Table 1: Characteristics of trials included in analysis.
Reference
N of participant,
Intervention/placebo
groups
Inclusion criteria Domperidone
dose
Domperidone
duration of
treatment
Outcome Outcome assessment
Petraglia et al.
[19] (1985) 9/8
Premiparous
mothers of term
infants with
insuﬃcient
lactationa 2w e e k s
post partum
30mg/day 10 days
Daily breast milk
yield, before and
after treatment,
mL/day
By weighing the infants
before and after
breastfeeding using an
electronic integrating scale
and summarizing the single
milk yields for the day
Da Silva et al.
[8] (2001) 7/9
Mothers of preterm
infants with low
milk productionb
30mg/day 7 days
Daily breast milk
volume, before and
after treatment,
mL/day
Mechanically expressed
breast milk by using a
double collecting pump
Campbell-Yeo
et al. [20]
(2010)
21/24
Mothers of preterm
infants (<31 weeks
gestation) with
lactation
failurec ≥3wks
after delivery
30mg/day 14 days
Daily breast milk
volume, before and
after treatment,
mL/day
Mechanically expressed
breast milk by using a
double collecting system
ainsuﬃcient lactation deﬁned as milk yields at least 30% lower than those reported as normal
blow milk production deﬁned as not meeting the infant’s daily oral feeding requirements
clactation failure deﬁned as not of the following: a decreasing milk supply by >30% from peak volume based on maternal count or inability to meet the daily
nutritional intake of the infant.
Table 2: Methodological quality of RCTs included in the meta-analysis.
Studies, year Sequence
generation
Allocation
concealment
Blinding of
participants and
personnel
Blinding of
outcome
assessment
Incomplete
outcome data
Selective
outcome
reporting
Other bias
Petraglia et al. [19]
(1985)
Insuﬃcient
informa-
tion/unclear
risk of bias
Insuﬃcient
informa-
tion/unclear risk
of bias
Insuﬃcient
informa-
tion/unclear risk
of bias
Insuﬃcient
informa-
tion/unclear risk
of bias
Insuﬃcient
informa-
tion/unclear risk
of bias
Insuﬃcient
informa-
tion/unclear
risk of bias
No/low
risk of bias
Da Silva et al. [8]
(2001)
Yes/low risk of
bias
Yes/low risk of
bias
Yes/low risk of
bias
Yes/low risk of
bias
Insuﬃcient
informa-
tion/unclear risk
of bias
No/low risk of
bias
No/low
risk of bias
Campbell-Yeo et al.
[20] (2011)
Yes/low risk of
bias
Yes/low risk of
bias
Yes/low risk of
bias
Yes/low risk of
bias
No/low risk of
bias
No/low risk of
bias
No/low
risk of bias
were judged as free of serious limitations and were graded as
high-quality evidence.
The study done by Petraglia et al. [19], to the con-
trary, did not provide suﬃcient information on sequence
generation and allocation concealment. Furthermore, the
study is described as a double-blind trial; however, there is
no information whether placebo and active drug were of
similarappearanceandtaste.Itisalsounclearfromthepaper
whether all women randomized initially completed the trial.
Given the above-mentioned limitations in the study design
and implementation, Petraglia et al. was downgraded from
high- to moderate-quality evidence.
3.4.ResultsofIndividualStudies. ThreeincludedRCTsevalu-
ated the eﬀect of domperidone on a daily breast milk volume
in the women with insuﬃcient lactation in comparison to
placebo.
Da Silva et al. reported that after 7-day treatment, the
mean daily milk volume had increased by 49.5 (SD = 29.4)
mL/day in the domperidone group compared to 8.0 (SD =
39.5) mL/day in the placebo group [8]. Similarly, Petraglia
et al. demonstrated that, following 10-day treatment, daily
milk yield was signiﬁcantly higher in a small group of
domperidone-treated mothers than that of the placebo-
treated group [19] .T h em e a ni n c r e a s ei nd a i l ym i l ky i e l d
was 326 (imputed SD = 21.4) mL/day after domperidone
versus 63 (imputed SD = 23.7) mL/day after placebo
treatment.
Finally, a signiﬁcant increase in daily breast milk produc-
tion was found in Campbell-Yeo et al. [20]: mean increase of
195.8 (imputed SD = 98.1) mL/day after a 14-day course of
domperidonecomparedto33.1(imputedSD=83.2)mL/day
in a placebo-treated group [20].
Overall, in absolute values, all three studies had shown a
statistically signiﬁcant increase from baseline in breast milk
production following treatment with domperidone.
Due to substantial diﬀerences in baseline milk volumes
across the studies, the relative changes from baseline wereObstetrics and Gynecology International 5
Study or subgroup
Domperidone
Mean Mean  SD SD Total Total Weight IV, random, 95% Cl 
Mean difference
IV, random, 95% Cl 
Mean difference Placebo
106.2
43.9
94
Total (95% cl)
53.2
26.1
6
21
7
9
37
15.2
16.4
19
38.2
82
7
24
9
91 [63.59, 118.41]
75 [68.76, 81.24]
74.72 [54.57, 94.86]
8
41
29.3%
10.5%
60.3%
100%
27.5 [−29.45, 84.45]
Heterogeneity: τ2 = 165.17;χ2 = 3.97,df = 2( P = .14);l2 = 50%
Test for overall eﬀect: Z = 7.27(P<. 00001)
Campbell-Yeo
DaSilva
Petraglia
−100 −50 0 50 100
Increase by placebo Increase by domperidone
Figure 2: Percent change in milk volume with domperidone treatment.
calculatedandusedtoestimate the pooled eﬀectofdomperi-
done (Figure 2).
3.5. Pooled Analysis. The analysis of pooled data demon-
strated a statistically signiﬁcant increase, of 74.7% (95% CI =
54.6; 94.9, P<0.00001) in daily milk production following
treatment with domperidone while comparing to placebo.
We observed a moderate statistical heterogeneity among the
studies (I2 = 50%).
4. Discussion
Our ﬁndings indicate that domperidone increases inade-
quate breast milk production in nursing mothers more eﬀec-
tively than placebo. A statistically signiﬁcant increase in the
mean change in daily breast milk volume from baseline was
observed in all three studies comparing domperidone and
placebo. This consistency of the domperidone eﬀect across
the studies enhances the conﬁdence of its beneﬁcial eﬀect as
agalactagogue.Importantly,nomaternalorneonataladverse
events were observed in any of the three trials. Although not
included in this analysis, the study by Wan and colleagues
demonstrated a dose-response increase in milk production,
further supporting our ﬁndings [12].
Another strength of the current meta-analysis lies in
the fact that, despite the paucity of published reports
on eﬀectiveness of domperidone to promote lactation, we
attempted to identify and include only randomized placebo-
controlled studies which are regarded as higher quality
evidence. Two out of the three included trials fulﬁlled the
GRADE criteria for high-quality evidence [8, 20], while
the third study [19] was downgraded to moderate-quality
evidence due to insuﬃcient details on study design and
execution and, therefore, as having a potential risk of bias.
Based on the moderate-high quality of evidence from
three RCTs, the pooled eﬀect of a 75% increase from
baseline in daily milk production following treatment with
domperidone is deemed to be clinically meaningful.
Our study has several limitations. Only three eligible
studies were found with small sample sizes (17, 16, and
45 participants in each trial, resp.). It has been suggested
that small trials with an insuﬃcient number of participants
and events may produce spurious treatment eﬀects due to
random error [25]. Furthermore, there have been reports
showing that some meta-analyses become inconclusive when
adjusted for random error risk [26, 27]. Hence, the calcula-
tion of optimal information size (similar to the concept of
sample size calculation for individual studies) and the use
of appropriate statistical tools (i.e., trial sequential analysis)
have been advocated to judge results of meta-analysis as
reliable and conclusive.
On the other hand, it is unclear how many studies are
needed to be included in meta-analysis to render results
trustworthy. Moreover, some researchers have demonstrated
that meta-analysis with a fewer trials do produce robust
results consistent with long-run ﬁndings [28]. However, it is
diﬃcult to foresee which results might be changed by sub-
sequent large-scale trials. Nonetheless, owing to the above-
mentionedlimitations,ourﬁndingsmustbeinterpretedwith
caution, and generalizable recommendations might be still
premature.
Additionally, a moderate statistical heterogeneity was
found to exist across the studies’ results. While all three trials
have utilized the same doses of domperidone (or placebo)
and reasonably similar duration of treatment, the diﬀerences
in study populations (mothers of preterm versus full-term
infants, breastfeeding or pumping their milk) and outcome
measurement instruments (increase in milk supply versus
infant weight gain) are likely to explain the observed hetero-
geneity. We have used a random eﬀects model for the pooled
estimate to deal with statistical heterogeneity. However, too
few studies available precluded subgroup analyses to further
explore the observed heterogeneity. We believe, though, that
the selected trials were methodologically sound to combine
in the present meta-analysis. The clinical relevance of this
modest heterogeneity is probably not meaningful as there
is a considerable consistency in domperidone eﬀect across
individual studies and no biological reason to suspect that
the opposite direction eﬀect might be true. Still, it is sensible
to investigate potential sources of heterogeneity as more
research on this topic becomes available.
One methodological challenge we encountered in the
present meta-analysis is not uncommon and thus deserves
special mention. The issue is related to handling missing
variance estimates data in primary studies included in meta-
analysis. Two out of three RCTs selected for our review
failed to provide standard deviations (SDs) for changes from
baselinewhichweselectedasaprimaryeﬀectmeasure. There
have been several methods proposed to impute missing
variance estimates for continuous outcomes [22–24]. Since
Da Silva et al. [8] reported SDs, we were able to calculate the
correlation coeﬃcient, a measurement of similarity between
the baseline and ﬁnal measurements across participants
from this study, and then apply the calculated value to
impute a change-from-baseline standard deviation for two6 Obstetrics and Gynecology International
other studies included in our meta-analysis. In general, a
correlation coeﬃcient of zero indicates no correlation which
is unusual for clinical outcomes as we expect certain degree
of association between measurements within an individual.
Similarly, a correlation coeﬃcient of one is unlikely due
to certain variability present within an individual. The
calculated correlations obtained from Da Silva et al. were
reasonably similar and close to 1 for the domperidone and
placebo groups (0.97 and 0.78, resp.). We used an average
correlationcoeﬃcientof0.875toimputethemissingchange-
from-baseline standard deviations for the remaining studies.
A sensitivity analysis was performed utilizing the lowest and
highest values of the correlation coeﬃcient and repeating
the analysis. This did not change our overall conclusion
as the pooled estimates and conﬁdence intervals were not
signiﬁcantly changed in terms of magnitude or directionality
(data not shown). Although a certain degree of uncertainty
exists regarding the accuracy of the results derived from this
approach, there is a growing body of the literature indicating
the validity of results from meta-analyses utilizing various
imputation methods [29, 30].
5. Conclusions
Currently available data from a few small randomized
controlled trials suggest that domperidone produces greater
increase in breast milk supply than that found with placebo
in some puerperal women with insuﬃcient milk production.
These results, however, should be interpreted in the context
of the limitations of available data. Additional randomized
clinical trials of adequate sample size are desirable and
might have an impact on our conﬁdence in the estimate
of domperidone eﬀect as a galactagogue. In the realm
of clinical practice, however, while the balance between
desirable and undesirable eﬀects often guides treatment
decisions, the current analysis supports consideration that
domperidone might be an eﬀective treatment option for
selected women with inadequate lactation. It appears to be
prudent though to try nonpharmacological interventions,
for example, maternal lactation education, ﬁrst [1, 5].
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